Equities research analysts at William Blair lowered their Q2 2026 earnings per share estimates for Zumiez in a report ...

Investment analysts at William Blair cut their Q1 2025 earnings per share (EPS) estimates for U.S. Physical Therapy in a ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

The stock gained 15% to $85.70 in trading Friday, putting it on track for its largest daily percentage increase since ...

Geopolitical tensions, trade conflicts, and major policy shifts are reshaping the global economy as we enter 2025. Click to ...